Topobexin targets the Topoisomerase II ATPase domain for beta isoform-selective inhibition and anthracycline cardioprotectionJan Kubeš, Matthew J. Schellenberg, Julia R Alvey et al.|Nature Communications|2025Cited by 14
Topobexin Targets a Unique Druggable Pocket of Topoisomerase II for Beta Isoform- Selective Control of DNA Damage During Anthracycline ChemotherapyJan Kubeš, Matthew J. Schellenberg, Galina Karabanovich et al.|Structural Dynamics|2025Cited by 0
Analysis of Gene Expression Changes upon Topobexin Treatment and TOP2B-knockout in hiPSC derived cardiomyocytesVeronika Keresteš, Caroline A. Austin, Ian G. Cowell et al.|bioRxiv (Cold Spring Harbor Laboratory)|2026Cited by 0
Structure-Guided Development of Topoisomerase IIB Isoform-Selective Inhibitors for Prevention of Anthracycline Cardiotoxicity (Abstract ID: 270109)Anh Cong, Matthew J. Schellenberg, Caroline A. Austin et al.|Journal of Pharmacology and Experimental Therapeutics|2026Cited by 0
Analysis of gene expression changes upon topobexin treatment and TOP2B-knockout in hiPSC-derived cardiomyocytesVeronika Keresteš, Caroline A. Austin, Ian G. Cowell et al.|Biology Open|2026Cited by 0